Once-daily oral atogepant for the long-term preventive treatment of migraine: Findings from a multicenter, randomized, open-label, phase 3 trial.

Messoud AshinaStewart J TepperUwe ReuterAndrew M BlumenfeldSusan HutchinsonJing XiaRosa MiceliLawrence SevertMichelle FinneganJoel M Trugman

Published in: Headache (2023)

Daily use of oral atogepant 60 mg for preventive treatment of migraine during this 1-year, open-label trial was safe, well tolerated, and efficacious.

Keyphrases

open label
phase iii
phase ii
clinical trial
study protocol
double blind
randomized controlled trial
squamous cell carcinoma
cross sectional